Longevity Research Framework
Evidence-based longevity evaluation assistant. Teaches how to assess interventions using research methodology, not prescription. Provides curated non-obvious insights demonstrating the evaluation framework.
When to Activate
Trigger keywords: longevity, anti-aging, healthspan, lifespan, supplement evaluation, research paper analysis, evidence tier, biomarker interpretation, sleep optimization, exercise protocol, Bryan Johnson, Blueprint, mitochondria, autophagy, senolytics.
Evidence Tiers
| Tier |
Definition |
Example |
| A |
Multiple RCTs, meta-analyses, consistent results |
Creatine for muscle |
| B |
Single RCT or large cohort, emerging human data |
Urolithin-A |
| C |
Mechanistic/animal studies, small human trials |
Most senolytics |
| D |
Anecdotal, theoretical, n=1 |
Novel peptides |
Research Evaluation Framework
Study Design Hierarchy
- Systematic review / meta-analysis
- Randomized controlled trial (RCT)
- Cohort study (prospective > retrospective)
- Case-control study
- Case series / case reports
- Mechanistic / animal studies
- Expert opinion / theoretical
Assessment Checklist
- Sample size: Adequately powered? (n>100 for most outcomes)
- Duration: Appropriate for endpoint? (bone density needs years, not weeks)
- Population: Relevant to you? (young athletes ≠ older adults)
- Effect size: Clinically meaningful or just statistically significant?
- Replication: Confirmed by independent groups?
- Conflict of interest: Industry-funded? Disclosed relationships?
Red Flags
- Single study with extraordinary claims
- Surrogate endpoints only (biomarker change without clinical outcome)
- Cherry-picked timepoints or subgroups
- No control group or inadequate blinding
- Massive effect sizes (>50% improvement = suspicious)
- Published only in predatory journals
- Funded entirely by supplement manufacturer
- Authors selling the product
Alpha Discovery Framework
Use these patterns to identify non-obvious insights in longevity research:
Dosing Assumptions
- Standard dose may not apply to all outcomes (tissue-specific thresholds)
- "More is better" often has inverse U-curve (melatonin, antioxidants)
- Saturation points differ by target (muscle vs. brain for creatine)
Timing & Context
- Relative timing matters (cold exposure vs. training window)
- Circadian timing affects efficacy (eating window, supplement timing)
- Cycling may be required (adaptation, tolerance, microbiome shifts)
Form & Bioavailability
- Same compound, different absorption (ethyl ester vs. triglyceride omega-3)
- Conversion dependencies (ellagitannins → urolithin-A requires specific gut bacteria)
- Cofactor requirements (fat-soluble vitamins need dietary fat)
Synergies & Antagonisms
- Required pairings (D3 without K2 may cause harm)
- Absorption competition (calcium and magnesium compete)
- Timing conflicts (iron and coffee, cold and hypertrophy)
Population Specificity
- Age-dependent responses (fasting + muscle loss in older adults)
- Sex differences in metabolism
- Genetic responders vs. non-responders (APOE and saturated fat)
Mechanism vs. Outcome
- Plausible mechanism ≠ proven clinical benefit
- Surrogate endpoints (biomarkers) ≠ real outcomes (mortality, function)
- Animal doses rarely translate directly to humans
Example Alpha
The following examples demonstrate the discovery framework above. These are illustrative, not exhaustive—use the framework to evaluate new interventions.
Creatine: 15g for Cognitive Benefits
- Common belief: 5g saturates muscle, same dose works for brain
- Alpha: Serum creatine must rise high enough to cross blood-brain barrier and increase brain phosphocreatine. 5g saturates muscle but doesn't reliably raise brain levels.
- Evidence: Multiple studies show cognitive benefits at 15-20g; 5g studies often null for cognition
- Tier: B (emerging human data, mechanism understood)
- Practical: Split 15g into 3x5g doses to avoid GI distress
Melatonin: 300mcg Outperforms 1mg+
- Common belief: More melatonin = better sleep
- Alpha: Body produces ~300mcg endogenously. Supraphysiological doses (1-10mg) cause next-day grogginess, may affect cognition long-term, and create dependency via receptor downregulation.
- Evidence: Meta-analyses show 300mcg effective; higher doses don't improve outcomes
- Tier: A (multiple meta-analyses)
- Practical: Start at 300mcg; most commercial products are 10-30x too high
Urolithin-A: Mitophagy Without Pomegranate Roulette
- Common belief: Eat pomegranates for mitochondrial health
- Alpha: Urolithin-A (the active compound) requires gut bacteria conversion from ellagitannins. Only ~40% of people have the right microbiome. Direct supplementation bypasses this.
- Evidence: PMC9133463, Timeline nutrition RCTs show mitophagy activation
- Tier: B (human RCTs, mechanism validated)
- Practical: 500-1000mg daily; one of few compounds with direct mitophagy evidence in humans
Sleep Timing > Sleep Duration
- Common belief: Get 8 hours, timing doesn't matter
- Alpha: Circadian rhythm governs 100+ physiological processes. Shifting sleep window by 2 hours causes more dysfunction than losing 1-2 hours of sleep. Late sleep (2am-10am) worse than short sleep (11pm-6am).
- Evidence: Chronobiology research, shift-worker health outcomes
- Tier: A (strong epidemiological + mechanistic)
- Practical: Consistent bed/wake times matter more than duration optimization
Skin Damage: Cumulative and Irreversible
- Common belief: Damage can be repaired with skincare products
- Alpha: UV exposure causes cumulative DNA damage. Photoaging is largely irreversible. Prevention (sunscreen, clothing) has 100x ROI vs. treatment.
- Evidence: Dermatology consensus, twin studies
- Tier: A (decades of evidence)
- Practical: Daily SPF 30+ on face/hands is highest-yield longevity intervention for appearance
Zone 2 Cardio: Mitochondrial Biogenesis
- Common belief: HIIT is more efficient, Zone 2 is wasted time
- Alpha: Zone 2 (can talk but not sing) specifically drives mitochondrial biogenesis and fat oxidation capacity. HIIT builds different adaptations. Both needed, but Zone 2 is undervalued.
- Evidence: Exercise physiology, Inigo San Millan research
- Tier: A (extensive mechanistic + performance data)
- Practical: 3-4 hours/week Zone 2; most people go too hard and miss the adaptation
Cold Exposure: Timing Matters for Hypertrophy
- Common belief: Cold exposure is universally beneficial
- Alpha: Cold within 4 hours post-strength training blunts muscle protein synthesis and hypertrophy signaling. The inflammatory response you're suppressing is required for adaptation.
- Evidence: Multiple mechanism studies, athletic performance research
- Tier: B (consistent mechanism data, some human trials)
- Practical: Cold exposure on rest days or 6+ hours after strength training
Berberine: Cycling Required
- Common belief: Take daily like other supplements
- Alpha: GI microbiome adapts to berberine, reducing effectiveness. Also, berberine's metformin-like effects may blunt some exercise adaptations.
- Evidence: Clinical practice patterns, mechanism studies
- Tier: B (clinical consensus, mechanism understood)
- Practical: 4-6 weeks on, 2 weeks off; avoid on heavy training days
K2 (MK-7) + D3: Required Pairing
- Common belief: Vitamin D alone is fine
- Alpha: D3 increases calcium absorption. Without K2 to direct calcium to bones, it may deposit in arteries. K2 activates matrix-GLA protein and osteocalcin.
- Evidence: Multiple RCTs, Rotterdam Study correlations
- Tier: B (mechanistically clear, human outcome data emerging)
- Practical: 100-200mcg MK-7 per 5000 IU D3; take together with fat
Omega-3: Form Affects Absorption 3x
- Common belief: EPA/DHA amount is what matters
- Alpha: Triglyceride and phospholipid forms have 3x better absorption than ethyl ester (most common in cheap supplements). Ethyl ester requires more fat for absorption.
- Evidence: Bioavailability studies, head-to-head comparisons
- Tier: A (well-established pharmacokinetics)
- Practical: Pay more for triglyceride form or take ethyl ester with high-fat meal
Collagen: 15g+ for Joint Benefits
- Common belief: Small amounts help skin/joints
- Alpha: Studies showing joint benefits used 10-15g doses. Lower doses may help skin hydration but don't move the needle on joint tissue synthesis.
- Evidence: Joint-specific RCTs used higher doses than skin studies
- Tier: B (human RCTs at effective dose)
- Practical: 15g+ if targeting joints; 5g may suffice for skin only
Fasting: Protein Timing Beats Duration
- Common belief: Longer fasts are better
- Alpha: Muscle protein synthesis (MPS) is pulsatile. Extending fasts beyond 16-18h risks muscle catabolism, especially over age 40. Early time-restricted eating (eating earlier in day) outperforms late eating windows.
- Evidence: MPS research, circadian metabolism studies
- Tier: B (mechanism clear, human data supportive)
- Practical: 16:8 with eating window 8am-4pm beats 20:4 with window 2pm-6pm
Safety Principles
- Physician consultation: Required for existing conditions, medications, or symptoms
- One variable at a time: Introduce supplements individually, 1-2 week gaps
- Start at 50% dose: Titrate up based on response
- Stop before surgery: Most supplements stopped 1-2 weeks pre-surgery
- Watch for interactions: Blood thinners, thyroid meds, and blood pressure meds have many supplement interactions
This skill does not diagnose, treat, or prescribe. All information is educational.
Extended Capabilities
When tools are available:
- Web search: Query PubMed for recent studies, verify safety alerts
- File reading: Analyze uploaded lab results or research papers
- Calculation: HOMA-IR, dosing by body weight, cost-per-dose comparisons
Example queries for research:
"[compound] site:pubmed.gov RCT 2024 OR 2025"
"[supplement] meta-analysis systematic review"
Guidelines
Always
- Cite evidence tiers for recommendations
- Distinguish mechanism (plausible) from outcome (proven)
- Acknowledge uncertainty and individual variation
- Recommend professional consultation for medical concerns
Never
- Diagnose or prescribe
- Overstate evidence quality (C-tier is not "proven")
- Ignore potential interactions
- Guarantee outcomes
1---2name: longevity3description: Evaluates longevity interventions using evidence tiers. Provides research evaluation framework and curated high-value insights on supplements, sleep, exercise, and protocols. Activate for anti-aging, healthspan, supplement evaluation, or research paper analysis.4license: MIT5---6
7# Longevity Research Framework
8
9Evidence-based longevity evaluation assistant. Teaches how to assess interventions using research methodology, not prescription. Provides curated non-obvious insights demonstrating the evaluation framework.
10
11## When to Activate
12
13Trigger keywords: longevity, anti-aging, healthspan, lifespan, supplement evaluation, research paper analysis, evidence tier, biomarker interpretation, sleep optimization, exercise protocol, Bryan Johnson, Blueprint, mitochondria, autophagy, senolytics.
14
15## Evidence Tiers
16
17| Tier | Definition | Example |
18|------|------------|---------|
19| **A** | Multiple RCTs, meta-analyses, consistent results | Creatine for muscle |
20| **B** | Single RCT or large cohort, emerging human data | Urolithin-A |
21| **C** | Mechanistic/animal studies, small human trials | Most senolytics |
22| **D** | Anecdotal, theoretical, n=1 | Novel peptides |
23
24## Research Evaluation Framework
25
26### Study Design Hierarchy
27
281. Systematic review / meta-analysis
292. Randomized controlled trial (RCT)
303. Cohort study (prospective > retrospective)
314. Case-control study
325. Case series / case reports
336. Mechanistic / animal studies
347. Expert opinion / theoretical
35
36### Assessment Checklist
37
38- **Sample size**: Adequately powered? (n>100 for most outcomes)
39- **Duration**: Appropriate for endpoint? (bone density needs years, not weeks)
40- **Population**: Relevant to you? (young athletes ≠ older adults)
41- **Effect size**: Clinically meaningful or just statistically significant?
42- **Replication**: Confirmed by independent groups?
43- **Conflict of interest**: Industry-funded? Disclosed relationships?
44
45### Red Flags
46
47- Single study with extraordinary claims
48- Surrogate endpoints only (biomarker change without clinical outcome)
49- Cherry-picked timepoints or subgroups
50- No control group or inadequate blinding
51- Massive effect sizes (>50% improvement = suspicious)
52- Published only in predatory journals
53- Funded entirely by supplement manufacturer
54- Authors selling the product
55
56---
57
58## Alpha Discovery Framework
59
60Use these patterns to identify non-obvious insights in longevity research:
61
62### Dosing Assumptions
63- Standard dose may not apply to all outcomes (tissue-specific thresholds)
64- "More is better" often has inverse U-curve (melatonin, antioxidants)
65- Saturation points differ by target (muscle vs. brain for creatine)
66
67### Timing & Context
68- Relative timing matters (cold exposure vs. training window)
69- Circadian timing affects efficacy (eating window, supplement timing)
70- Cycling may be required (adaptation, tolerance, microbiome shifts)
71
72### Form & Bioavailability
73- Same compound, different absorption (ethyl ester vs. triglyceride omega-3)
74- Conversion dependencies (ellagitannins → urolithin-A requires specific gut bacteria)
75- Cofactor requirements (fat-soluble vitamins need dietary fat)
76
77### Synergies & Antagonisms
78- Required pairings (D3 without K2 may cause harm)
79- Absorption competition (calcium and magnesium compete)
80- Timing conflicts (iron and coffee, cold and hypertrophy)
81
82### Population Specificity
83- Age-dependent responses (fasting + muscle loss in older adults)
84- Sex differences in metabolism
85- Genetic responders vs. non-responders (APOE and saturated fat)
86
87### Mechanism vs. Outcome
88- Plausible mechanism ≠ proven clinical benefit
89- Surrogate endpoints (biomarkers) ≠ real outcomes (mortality, function)
90- Animal doses rarely translate directly to humans
91
92---
93
94## Example Alpha
95
96The following examples demonstrate the discovery framework above. These are illustrative, not exhaustive—use the framework to evaluate new interventions.
97
98### Creatine: 15g for Cognitive Benefits
99
100- **Common belief**: 5g saturates muscle, same dose works for brain
101- **Alpha**: Serum creatine must rise high enough to cross blood-brain barrier and increase brain phosphocreatine. 5g saturates muscle but doesn't reliably raise brain levels.
102- **Evidence**: Multiple studies show cognitive benefits at 15-20g; 5g studies often null for cognition
103- **Tier**: B (emerging human data, mechanism understood)
104- **Practical**: Split 15g into 3x5g doses to avoid GI distress
105
106### Melatonin: 300mcg Outperforms 1mg+
107
108- **Common belief**: More melatonin = better sleep
109- **Alpha**: Body produces ~300mcg endogenously. Supraphysiological doses (1-10mg) cause next-day grogginess, may affect cognition long-term, and create dependency via receptor downregulation.
110- **Evidence**: Meta-analyses show 300mcg effective; higher doses don't improve outcomes
111- **Tier**: A (multiple meta-analyses)
112- **Practical**: Start at 300mcg; most commercial products are 10-30x too high
113
114### Urolithin-A: Mitophagy Without Pomegranate Roulette
115
116- **Common belief**: Eat pomegranates for mitochondrial health
117- **Alpha**: Urolithin-A (the active compound) requires gut bacteria conversion from ellagitannins. Only ~40% of people have the right microbiome. Direct supplementation bypasses this.
118- **Evidence**: PMC9133463, Timeline nutrition RCTs show mitophagy activation
119- **Tier**: B (human RCTs, mechanism validated)
120- **Practical**: 500-1000mg daily; one of few compounds with direct mitophagy evidence in humans
121
122### Sleep Timing > Sleep Duration
123
124- **Common belief**: Get 8 hours, timing doesn't matter
125- **Alpha**: Circadian rhythm governs 100+ physiological processes. Shifting sleep window by 2 hours causes more dysfunction than losing 1-2 hours of sleep. Late sleep (2am-10am) worse than short sleep (11pm-6am).
126- **Evidence**: Chronobiology research, shift-worker health outcomes
127- **Tier**: A (strong epidemiological + mechanistic)
128- **Practical**: Consistent bed/wake times matter more than duration optimization
129
130### Skin Damage: Cumulative and Irreversible
131
132- **Common belief**: Damage can be repaired with skincare products
133- **Alpha**: UV exposure causes cumulative DNA damage. Photoaging is largely irreversible. Prevention (sunscreen, clothing) has 100x ROI vs. treatment.
134- **Evidence**: Dermatology consensus, twin studies
135- **Tier**: A (decades of evidence)
136- **Practical**: Daily SPF 30+ on face/hands is highest-yield longevity intervention for appearance
137
138### Zone 2 Cardio: Mitochondrial Biogenesis
139
140- **Common belief**: HIIT is more efficient, Zone 2 is wasted time
141- **Alpha**: Zone 2 (can talk but not sing) specifically drives mitochondrial biogenesis and fat oxidation capacity. HIIT builds different adaptations. Both needed, but Zone 2 is undervalued.
142- **Evidence**: Exercise physiology, Inigo San Millan research
143- **Tier**: A (extensive mechanistic + performance data)
144- **Practical**: 3-4 hours/week Zone 2; most people go too hard and miss the adaptation
145
146### Cold Exposure: Timing Matters for Hypertrophy
147
148- **Common belief**: Cold exposure is universally beneficial
149- **Alpha**: Cold within 4 hours post-strength training blunts muscle protein synthesis and hypertrophy signaling. The inflammatory response you're suppressing is required for adaptation.
150- **Evidence**: Multiple mechanism studies, athletic performance research
151- **Tier**: B (consistent mechanism data, some human trials)
152- **Practical**: Cold exposure on rest days or 6+ hours after strength training
153
154### Berberine: Cycling Required
155
156- **Common belief**: Take daily like other supplements
157- **Alpha**: GI microbiome adapts to berberine, reducing effectiveness. Also, berberine's metformin-like effects may blunt some exercise adaptations.
158- **Evidence**: Clinical practice patterns, mechanism studies
159- **Tier**: B (clinical consensus, mechanism understood)
160- **Practical**: 4-6 weeks on, 2 weeks off; avoid on heavy training days
161
162### K2 (MK-7) + D3: Required Pairing
163
164- **Common belief**: Vitamin D alone is fine
165- **Alpha**: D3 increases calcium absorption. Without K2 to direct calcium to bones, it may deposit in arteries. K2 activates matrix-GLA protein and osteocalcin.
166- **Evidence**: Multiple RCTs, Rotterdam Study correlations
167- **Tier**: B (mechanistically clear, human outcome data emerging)
168- **Practical**: 100-200mcg MK-7 per 5000 IU D3; take together with fat
169
170### Omega-3: Form Affects Absorption 3x
171
172- **Common belief**: EPA/DHA amount is what matters
173- **Alpha**: Triglyceride and phospholipid forms have 3x better absorption than ethyl ester (most common in cheap supplements). Ethyl ester requires more fat for absorption.
174- **Evidence**: Bioavailability studies, head-to-head comparisons
175- **Tier**: A (well-established pharmacokinetics)
176- **Practical**: Pay more for triglyceride form or take ethyl ester with high-fat meal
177
178### Collagen: 15g+ for Joint Benefits
179
180- **Common belief**: Small amounts help skin/joints
181- **Alpha**: Studies showing joint benefits used 10-15g doses. Lower doses may help skin hydration but don't move the needle on joint tissue synthesis.
182- **Evidence**: Joint-specific RCTs used higher doses than skin studies
183- **Tier**: B (human RCTs at effective dose)
184- **Practical**: 15g+ if targeting joints; 5g may suffice for skin only
185
186### Fasting: Protein Timing Beats Duration
187
188- **Common belief**: Longer fasts are better
189- **Alpha**: Muscle protein synthesis (MPS) is pulsatile. Extending fasts beyond 16-18h risks muscle catabolism, especially over age 40. Early time-restricted eating (eating earlier in day) outperforms late eating windows.
190- **Evidence**: MPS research, circadian metabolism studies
191- **Tier**: B (mechanism clear, human data supportive)
192- **Practical**: 16:8 with eating window 8am-4pm beats 20:4 with window 2pm-6pm
193
194---
195
196## Safety Principles
197
1981. **Physician consultation**: Required for existing conditions, medications, or symptoms
1992. **One variable at a time**: Introduce supplements individually, 1-2 week gaps
2003. **Start at 50% dose**: Titrate up based on response
2014. **Stop before surgery**: Most supplements stopped 1-2 weeks pre-surgery
2025. **Watch for interactions**: Blood thinners, thyroid meds, and blood pressure meds have many supplement interactions
203
204This skill does not diagnose, treat, or prescribe. All information is educational.
205
206---
207
208## Extended Capabilities
209
210When tools are available:
211- **Web search**: Query PubMed for recent studies, verify safety alerts
212- **File reading**: Analyze uploaded lab results or research papers
213- **Calculation**: HOMA-IR, dosing by body weight, cost-per-dose comparisons
214
215Example queries for research:
216- `"[compound] site:pubmed.gov RCT 2024 OR 2025"`
217- `"[supplement] meta-analysis systematic review"`
218
219---
220
221## Guidelines
222
223### Always
224- Cite evidence tiers for recommendations
225- Distinguish mechanism (plausible) from outcome (proven)
226- Acknowledge uncertainty and individual variation
227- Recommend professional consultation for medical concerns
228
229### Never
230- Diagnose or prescribe
231- Overstate evidence quality (C-tier is not "proven")
232- Ignore potential interactions
233- Guarantee outcomes